RT Journal Article
SR Electronic
T1 The circulating proteome and brain health: Mendelian randomisation and cross-sectional analyses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.27.23293236
DO 10.1101/2023.07.27.23293236
A1 Walker, Rosie M.
A1 Chong, Michael
A1 Perrot, Nicolas
A1 Pigeyre, Marie
A1 Gadd, Danni A.
A1 Stolicyn, Aleks
A1 Shi, Liu
A1 Campbell, Archie
A1 Shen, Xueyi
A1 Whalley, Heather C.
A1 Nevado-Holgado, Alejo
A1 McIntosh, Andrew M.
A1 Heitmeier, Stefan
A1 Rangarajan, Sumathy
A1 O’Donnell, Martin
A1 Smith, Eric E.
A1 Yusuf, Salim
A1 Whiteley, William N.
A1 Paré, Guillaume
YR 2023
UL http://medrxiv.org/content/early/2023/07/31/2023.07.27.23293236.abstract
AB Background Decline in cognitive function is the most feared aspect of ageing. Poorer midlife cognitive function is associated with increased dementia and stroke risk. The mechanisms underlying variation in cognitive function are uncertain.Methods We assessed associations between 1160 proteins’ plasma levels and two measures of cognitive function, the digit symbol substitution test (DSST) and the Montreal Cognitive Assessment in 1198 PURE-MIND participants. We assessed key MRI-ascertained structural brain phenotypes as potential mediators of associations between plasma protein levels and cognitive function. Potentially causal effects of protein levels on structural brain phenotypes and neurological outcomes were assessed using Mendelian randomisation (MR) analyses.Results We identified five DSST performance-associated proteins (NCAN, BCAN, CA14, MOG, CDCP1), with NCAN and CDCP1 showing replicated association in an independent cohort, GS (N=1053). MRI-assessed structural brain phenotypes partially mediated (8-19%) associations between NCAN, BCAN, and MOG, and DSST performance. MR analyses suggested higher CA14 levels might cause larger hippocampal volume and increased stroke risk, whilst higher CDCP1 levels might increase stroke and intracranial aneurysm risk.Conclusions We identify cognition-associated plasma proteins with potentially causal effects on brain structure and risk for neurological diseases. Our findings highlight candidates for further study and the potential for drug repurposing to reduce risk of stroke and cognitive decline.Competing Interest StatementMC is supported by a Canadian Institute of Health Research doctoral award and has received consulting fees from Bayer AG. MP is supported by the EJ Moran Campbell Internal Career Research Award from McMaster University. DAG is a part-time employee of Optima partners, a health data consultancy based at the Bayes centre, The University of Edinburgh. SH is an employee of Bayer AG. AMM has previously received speaker's fees from Illumina and Janssen and research grant funding from The Sackler Trust. SY is supported by the Heart and Stroke Foundation/Marion W Burke Chair in Cardiovascular Disease. GP is supported by the CISCO Professorship in Integrated Health Systems. The other authors declare no competing interests.Funding StatementPURE The PURE study is an investigator initiated study that is funded by the Population Health Research Institute, the Canadian Institutes of Health Research (CIHR), Heart and Stroke Foundation of Ontario, support from CIHR's Strategy for Patient Oriented Research, through the Ontario SPOR Support Unit, as well as the Ontario Ministry of Health and Long Term Care and through unrestricted grants from several pharmaceutical companies (with major contributions from AstraZeneca [Canada], Sanofi Aventis [France and Canada], Boehringer Ingelheim [Germany and Canada], Servier, and GlaxoSmithKline), and additional contributions from Novartis and King Pharma and from various national or local organisations in participating countries as follows: Argentina, Fundacion ECLA; Bangladesh, Independent University, Bangladesh and Mitra and Associates; Brazil, Unilever Health Institute, Brazil; Canada, Public Health Agency of Canada and Champlain Cardiovascular Disease Prevention Network; Chile, Universidad de la Frontera; Colombia, Colciencias (grant number 6566 04 18062); South Africa, The North West University, SANPAD (SA and Netherlands Programme for Alternative Development), National Research Foundation, Medical Research Council of South Africa, The South Africa Sugar Association, Faculty of Community and Health Sciences; Sweden, grants from the Swedish State under the Agreement concerning research and education of doctors, the Swedish Heart and Lung Foundation, the Swedish Research Council, the Swedish Council for Health, Working Life and Welfare, King Gustaf V's and Queen Victoria Freemasons Foundation, AFA Insurance, Swedish Council for Working Life and Social Research, Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning, grant from the Swedish State under (L&aumlkarUtbildningsAvtalet) Agreement, and grant from the V&aumlstra G&oumltaland Region; and United Arab Emirates, Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences, Dubai Health Authority, Dubai. The PURE biomarker project was supported by Bayer and the CIHR. The biomarker project was led by PURE investigators at the Population Health Research Institute (Hamilton, Canada) in collaboration with Bayer scientists. Bayer directly compensated the Population Health Research Institute for measurement of the biomarker panels, scientific, methodological, and statistical work. Genetic analyses were supported by CIHR (G 18 0022359) and Heart and Stroke Foundation of Canada (application number 399497) in the form of funding to GP. GS This work was supported by the Wellcome Trust [104036/Z/14/Z, 220857/Z/20/Z, and 216767/Z/19/Z] and an MRC Mental Health Data Pathfinder Grant [MCPC17209] to AMM. DAG is funded by the Wellcome Trust Translational Neuroscience PhD Programme at the University of Edinburgh [108890/Z/15/Z]. LS and ANH are supported by Medical Research Council [MR/L023784/2]: Dementias Platform UK. LS is also supported by a Medical Research Council Award to the University of Oxford [MCPC17215]. AS is supported through the Wellcome-University of Edinburgh Institutional Strategic Support Fund (Reference 204804/Z/16/Z), and indirectly through the Lister Institute of Preventive Medicine award with reference 173096. Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006]. Genotyping of the GS:SFHS samples was carried out by the Genetics Core Laboratory at the Clinical Research Facility, Edinburgh, Scotland, and was funded by the UK's Medical Research Council and the Wellcome Trust [104036/Z/14/Z]. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The PURE study was approved by the Institutional Review Board of Hamilton Health Sciences (H14-02982), and the local ethics committees in the participating countries. All components of Generation Scotland received ethical approval from the NHS Tayside Committee on Medical Research Ethics (REC Reference Number: 05/S1401/89). All participants provided broad and enduring written informed consent for biomedical research. Generation Scotland has also been granted Research Tissue Bank status by the East of Scotland Research Ethics Service (REC Reference Number: 15/0040/ES), providing generic ethical approval for a wide range of uses within medical research.. The imaging subsample of Generation Scotland received ethical approval from the NHS Tayside committee on research ethics (reference 14/SS/0039). This study was performed in accordance with the Helsinki declaration. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe PURE datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. According to the terms of consent for GS participants, access to individual-level data (omics and phenotypes) must be reviewed by the GS Access Committee. Applications should be made to access@generationscotland.org. ACMEAverage causal mediation effectBCANbrevicanCA14carbonic anhydrase 14CD6cluster of differentiation 6CDCP1CUB-domain containing protein 1CIconfidence intervalCMBcerebral microbleedCSFcerebrospinal fluidDSSTdigit symbol substitution testECMextracellular matrixFDRfalse discovery rateGSGeneration Scotland imaging subsampleGS:SFHSGeneration Scotland: Scottish Family Health StudyIVinstrumental variableIVWinverse variance weightedMOGmyelin oligodendrocyte glycoproteinMoCAMontreal Cognitive AssessmentMRMendelian randomisationMRImagnetic resonance imagingNCANneurocanPNNperineuronal netORodds ratioPPposterior probabilitypQTLprotein quantitative trait lociPWCoCopairwise conditional analysis and co-localisation analysesPUREProspective Urban and Rural EpidemiologyRAPSrobust adjusted profile scoreSBIsilent brain infarctSDstandard deviationSVDsmall vessel diseaseWMHwhite matter hyperintensity